tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CR Boya Bio-pharmaceutical Reports Mixed Financial Results for H1 2025

Story Highlights
CR Boya Bio-pharmaceutical Reports Mixed Financial Results for H1 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.

CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported a 12.51% increase in revenue for the first half of 2025 compared to the same period in 2024. However, the company experienced a significant decline in net profit attributable to shareholders by 28.68%, along with a drastic reduction in net cash flow from operating activities by 96.72%, indicating potential challenges in operational efficiency and profitability.

The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development and production of bio-pharmaceutical products. Its subsidiary, CR Boya Bio-pharmaceutical, is listed on the Shenzhen Stock Exchange and is involved in the bio-pharmaceutical sector, with the Group holding significant share capital and voting rights.

Average Trading Volume: 11,891,732

Technical Sentiment Signal: Sell

Current Market Cap: HK$33.05B

For detailed information about 3320 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1